Xenetic Biosciences (NASDAQ:XBIO) reported a 19% increase in royalty revenue for the full year 2025, providing a financial cushion as the company moves closer to human clinical trials for its lead immuno-oncology program.
The Framingham, Massachusetts-based developer of cancer therapies ended the year with a net loss of $2.7 million, an improvement over previous fiscal cycles, while maintaining a cash position of $7.9 million to fund its ongoing research and development efforts.
The company’s financial stability was bolstered by approximately $3 million in royalty income, primarily generated from its long-standing sublicense agreement with Takeda Pharmaceuticals.
This steady revenue stream, combined with an underwritten public offering completed in late 2025, has extended Xenetic’s operational runway as it prioritizes its DNase I platform.
The technology targets neutrophil extracellular traps (NETs)—web-like structures in the body that can shield tumors from the immune system—to improve the efficacy of existing treatments like chemotherapy and CAR-T cell therapies.
On the scientific front, Xenetic transitioned from early proof-of-concept work to more intensive IND-enabling activities.